For adults with systemic lupus erythematosus (SLE) and cutaneous disease, what are the effects of intravenous (IV)/subcutaneous (SC) monoclonal antibodies?

2021 ◽  
Author(s):  
Agustín Ciapponi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Monoclonal Antibodies ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Cutaneous Disease

Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus

Immunotherapy ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 255-270 ◽  
Author(s):  
Natasha Jordan ◽  
Pamela MK Lutalo ◽  
David P D’Cruz
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Monoclonal Antibodies ◽  
Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals Monoclonal antibodies RB139 and RB142 recognize citrullinated LL37 by immunofluorescence in histological sections in Systemic lupus erythematosus (SLE) and Rheumatoid arthritis (RA)

2020 ◽  
Vol 3 (4) ◽  
pp. e236
Author(s):  
Roberto Lande ◽  
Stefano Alivernini ◽  
Barbara Tolusso ◽  
Francesca Spadaro ◽  
Mario Falchi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Monoclonal Antibodies ◽  
Epithelial Cells ◽  
Lupus Erythematosus ◽  
Human Tissues ◽  
Systemic Lupus ◽  
Exact Localization ◽  
Health And Disease ◽  
Pleiotropic Functions

LL37 is a natural antibiotic, but is also a molecule with pleiotropic functions as well as an immune-modulator. LL37 is produced by epithelial cells and is present in neutrophils’ granules. LL37 alone, or in complex with DNA, can activate inflammatory pathways in psoriasis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In this work, we describe the capacity of two recombinant monoclonal antibodies, RB139 and RB142, previously shown to specifically recognize LL37 in its citrullinated form (cit-LL37) by ELISA, to detect LL37 by immunofluorescence in human inflamed tissues derived from SLE and RA patients. Such antibodies represent previously unavailable tools to detect the presence, the citrullinated state and the exact localization of cit-LL37 in human tissues in health and disease.

scholarly journals Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)

2010 ◽  
Vol 3 (1) ◽  
pp. 300-322 ◽  
Author(s):  
Claudio Ponticelli ◽  
Gabriella Moroni
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Monoclonal Antibodies ◽  
Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction

2001 ◽  
Vol 194 (12) ◽  
pp. 1823-1834 ◽  
Author(s):  
Andrzej Dzionek ◽  
Yoshiaki Sohma ◽  
Jun Nagafune ◽  
Marina Cella ◽  
Marco Colonna ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dendritic Cells ◽  
Monoclonal Antibodies ◽  
Dendritic Cell ◽  
Lupus Erythematosus ◽  
Plasmacytoid Dendritic Cell ◽  
Plasmacytoid Dendritic Cells ◽  
Interferon Α ◽  
Type Ii ◽  
Systemic Lupus

Plasmacytoid dendritic cells are present in lymphoid and nonlymphoid tissue and contribute substantially to both innate and adaptive immunity. Recently, we have described several monoclonal antibodies that recognize a plasmacytoid dendritic cell-specific antigen, which we have termed BDCA-2. Molecular cloning of BDCA-2 revealed that BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. Anti–BDCA-2 monoclonal antibodies are rapidly internalized and efficiently presented to T cells, indicating that BDCA-2 could play a role in ligand internalization and presentation. Furthermore, ligation of BDCA-2 potently suppresses induction of interferon α/β production in plasmacytoid dendritic cells, presumably by a mechanism dependent on calcium mobilization and protein-tyrosine phosphorylation by src-family protein-tyrosine kinases. Inasmuch as production of interferon α/β by plasmacytoid dendritic cells is considered to be a major pathophysiological factor in systemic lupus erythematosus, triggering of BDCA-2 should be evaluated as therapeutic strategy for blocking production of interferon α/β in systemic lupus erythematosus patients.

Sign in / Sign up

Export Citation Format

Share Document